Xconomy – Histogenics, a regenerative medicine company based in Waltham, MA, has closed $49 million in new financing led by Sofinnova Ventures.
The deal is being called a Series A financing round for the company. According to our records, however, Histogenics has raised more than $40 million in equity and debt funding since 2008. The company started back in 2000 and acquired ProChon BioTech in a stock deal last year. Today’s financing is a traditional recapitalization, not a restart, according to a company spokesperson.
Histogenics is in the middle of clinical trials for its lead product candidate, called NeoCart. This is a tissue implant that uses a patient’s own cells to grow cartilage outside the body for the purpose of repairing cartilage lesions in the knee. The company has another product candidate, called VeriCart, that uses a tissue-engineering approach involving stem cells and a collagen scaffold to repair cartilage defects. That product is slated for the European market, pending regulatory clearance.
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks
Wang is a prolific business-oriented writer of emerging and disruptive technologies. He is known for insightful articles that combine business and technical analysis that catches the attention of the general public and is also useful for those in the industries. He is the sole author and writer of nextbigfuture.com
, the top online science blog. He is also involved in angel investing and raising funds for breakthrough technology startup companies.
He gave the recent keynote presentation at Monte Jade event with a talk entitled the Future for You. He gave an annual update on molecular nanotechnology at Singularity University on nanotechnology, gave a TEDX talk on energy, and advises USC ASTE 527 (advanced space projects program). He has been interviewed for radio, professional organizations. podcasts and corporate events. He was recently interviewed by the radio program Steel on Steel on satellites and high altitude balloons that will track all movement in many parts of the USA.
He fundraises for various high impact technology companies and has worked in computer technology, insurance, healthcare and with corporate finance.
He has substantial familiarity with a broad range of breakthrough technologies like age reversal and antiaging, quantum computers, artificial intelligence, ocean tech, agtech, nuclear fission, advanced nuclear fission, space propulsion, satellites, imaging, molecular nanotechnology, biotechnology, medicine, blockchain, crypto and many other areas.